Indian Journal of Critical Care Case Report

Register      Login

VOLUME 1 , ISSUE 1 ( July-August, 2022 ) > List of Articles


Role of High-flow Nasal Cannula in Postprocedure Management of Whole Lung Lavage for Pulmonary Alveolar Proteinosis

Jyothis MC, Bhargava Venkata Devarakonda

Keywords : Anti-GM-CSF antibodies, High-flow nasal cannula, Pulmonary alveolar proteinosis, Whole lung lavage

Citation Information : MC J, Devarakonda BV. Role of High-flow Nasal Cannula in Postprocedure Management of Whole Lung Lavage for Pulmonary Alveolar Proteinosis. 2022; 1 (1):4-6.

DOI: 10.5005/jp-journals-11006-0002

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Pulmonary alveolar proteinosis (PAP) is a rare lung disorder.1 Primary autoimmune PAP is the most common form of PAP.2,3 The current standard of care in primary PAP is whole lung lavage (WLL) but the procedure has not yet been standardized. Studies about the use of high-flow nasal cannula (HFNC) in various conditions management have been found promising.4 However, use of HFNC particularly in the postprocedure period in patients who have undergone WLL has not been reported. Herein we present our experience with a patient with primary autoimmune PAP who underwent therapeutic WLL and managed with HFNC in the postprocedure period.

PDF Share
  1. Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers 2019;5(1):16. DOI: 10.1038/s41572-019-0066-3
  2. McCarthy C, Avetisyan R, Carey BC, et al. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis 2018;13(1):129. DOI: 10.1186/s13023-018-0846-y
  3. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008;177(7):752–762. DOI: 10.1164/rccm.200708-1271OC
  4. Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care 2016;61(4):529–541. DOI: 10.4187/respcare.04577
  5. Awab A, Khan MS, Youness HA. Whole lung lavage—technical details, challenges and management of complications. J Thorac Dis 2017;9(6):1697–1706. DOI: 10.21037/jtd.2017.04.10
  6. Campo I, Luisetti M, Griese M, et al. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet J Rare Dis 2016;11(1):115. DOI: 10.1186/s13023-016-0497-9
  7. Marwah V, Katoch CDS, Singh S, et al. Management of primary pulmonary alveolar proteinosis: a multicentric experience. Lung India 2020;37(4):304–309. DOI: 10.4103/lungindia.lungindia_401_19
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.